TY - JOUR
T1 - Cell-based therapy for Crohn’s disease
T2 - time to consider optimization
AU - Lightner, Amy
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Cell-based therapies for the treatment of perianal Crohn’s disease have well-established safety profiles and improved efficacy compared with conventional therapy. However, stem cells are not a homogeneous product and questions remain before we can optimize clinical trials of these treatments and achieve best patient outcomes.
AB - Cell-based therapies for the treatment of perianal Crohn’s disease have well-established safety profiles and improved efficacy compared with conventional therapy. However, stem cells are not a homogeneous product and questions remain before we can optimize clinical trials of these treatments and achieve best patient outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85058189049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058189049&partnerID=8YFLogxK
U2 - 10.1038/s41575-018-0095-5
DO - 10.1038/s41575-018-0095-5
M3 - Article
C2 - 30532061
AN - SCOPUS:85058189049
SN - 1759-5045
JO - Nature Reviews Gastroenterology and Hepatology
JF - Nature Reviews Gastroenterology and Hepatology
ER -